Other languages Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
50.85 ^USD	-1.15%		+14.81%	+37.58%

Jun. 07	Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $58 From $48, Maintains Overweight Rating	MT
Jun. 07	HC Wainwright Raises Price Target on Halozyme Therapeutics to $65 From $50, Maintains Buy Rating	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Lyft, Amazon, Fedex, Xpo, Vail Resorts, Unilever...	Jun. 07
Halozyme Therapeutics Lifts 2024 Guidance -- Shares Surge	Jun. 06
Sector Update: Health Care Stocks Steady Premarket Thursday	Jun. 06
Halozyme Therapeutics Lifts 2024 Guidance; Shares Rise Pre-Bell	Jun. 06
Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024	Jun. 06
Halozyme Therapeutics Gets European Patent for Enhanze Drug Delivery Platform	Jun. 05
Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing	May. 22
Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	May. 07
Halozyme Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024	May. 07
Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors	Apr. 25
Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	Apr. 18
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	Mar. 13
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance	Feb. 21
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 20
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.	Feb. 20
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 20
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.	Jan. 31
Halozyme Announces Takeda Receives European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	Jan. 29
Halozyme Therapeutics Insider Sold Shares Worth $720,000, According to a Recent SEC Filing	Jan. 18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Other languages

Filters